Alkermes (ALKS) Non-Current Assets (2011 - 2026)
Alkermes (ALKS) posted quarterly Non-Current Assets of $2.9 billion for Q2 2026, up 364.8% year-over-year from $617.5 million in Q2 2025, and down 1.01% quarter-over-quarter from $2.9 billion in Q1 2026.
Alkermes (ALKS) Non-Current Assets (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Non-Current Assets for 16 consecutive years, with $2.9 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets rose 364.8% year-over-year to $2.9 billion; the TTM figure through Jun 2026 stood at $6.9 billion (up 182.05% YoY), while the FY2025 annual figure was $557.8 million, down 12.87% from the prior year.
- Non-Current Assets retreated to $2.9 billion in Q2 2026 per ALKS's latest filing, from $2.9 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.9 billion in Q1 2026 and bottomed at $557.8 million in Q4 2025.
- Historically, Non-Current Assets has averaged $963.9 million across 5 years, with a median of $727.2 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Assets retreated 27.42% — and 2026, when it soared 380.89%.
- Alkermes' Non-Current Assets stood at $833.7 million in 2022, then fell by 21.95% to $650.7 million in 2023, then declined by 1.61% to $640.2 million in 2024, then retreated by 12.87% to $557.8 million in 2025, then jumped by 414.53% to $2.9 billion in 2026.
- Business Quant data shows ALKS's Non-Current Assets at $2.9 billion in Q2 2026, $2.9 billion in Q1 2026, and $557.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.87 Bn |
| Mar 31, 2026 | 2.90 Bn |
| Dec 31, 2025 | 557.83 Mn |
| Sep 30, 2025 | 587.85 Mn |
| Jun 30, 2025 | 617.52 Mn |
| Mar 31, 2025 | 602.93 Mn |
| Dec 31, 2024 | 640.21 Mn |
| Sep 30, 2024 | 591.11 Mn |
| Jun 30, 2024 | 664.65 Mn |
| Mar 31, 2024 | 655.07 Mn |
| Dec 31, 2023 | 650.72 Mn |
| Sep 30, 2023 | 814.45 Mn |
| Jun 30, 2023 | 789.83 Mn |
| Mar 31, 2023 | 812.67 Mn |
| Dec 31, 2022 | 833.67 Mn |
| Sep 30, 2022 | 888.10 Mn |
| Jun 30, 2022 | 911.43 Mn |
| Mar 31, 2022 | 963.02 Mn |
| Dec 31, 2021 | 962.32 Mn |
| Sep 30, 2021 | 942.43 Mn |